JPWO2020160020A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020160020A5 JPWO2020160020A5 JP2021543372A JP2021543372A JPWO2020160020A5 JP WO2020160020 A5 JPWO2020160020 A5 JP WO2020160020A5 JP 2021543372 A JP2021543372 A JP 2021543372A JP 2021543372 A JP2021543372 A JP 2021543372A JP WO2020160020 A5 JPWO2020160020 A5 JP WO2020160020A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- administered
- individual
- antibody
- dexamethasone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025115594A JP2025148430A (ja) | 2019-01-28 | 2025-07-09 | 多発性骨髄腫の処置方法 |
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962797876P | 2019-01-28 | 2019-01-28 | |
| US62/797,876 | 2019-01-28 | ||
| US201962847826P | 2019-05-14 | 2019-05-14 | |
| US62/847,826 | 2019-05-14 | ||
| US201962861954P | 2019-06-14 | 2019-06-14 | |
| US62/861,954 | 2019-06-14 | ||
| US201962899094P | 2019-09-11 | 2019-09-11 | |
| US62/899,094 | 2019-09-11 | ||
| US201962931014P | 2019-11-05 | 2019-11-05 | |
| US62/931,014 | 2019-11-05 | ||
| EP19306554.7 | 2019-12-03 | ||
| EP19306554 | 2019-12-03 | ||
| US201962943716P | 2019-12-04 | 2019-12-04 | |
| US62/943,716 | 2019-12-04 | ||
| PCT/US2020/015455 WO2020160020A1 (en) | 2019-01-28 | 2020-01-28 | Methods of treating multiple myeloma |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025115594A Division JP2025148430A (ja) | 2019-01-28 | 2025-07-09 | 多発性骨髄腫の処置方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022518060A JP2022518060A (ja) | 2022-03-11 |
| JP2022518060A5 JP2022518060A5 (https=) | 2023-02-22 |
| JPWO2020160020A5 true JPWO2020160020A5 (https=) | 2023-02-22 |
| JP7712206B2 JP7712206B2 (ja) | 2025-07-23 |
Family
ID=69646031
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021543372A Active JP7712206B2 (ja) | 2019-01-28 | 2020-01-28 | 多発性骨髄腫の処置方法 |
| JP2025115594A Pending JP2025148430A (ja) | 2019-01-28 | 2025-07-09 | 多発性骨髄腫の処置方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025115594A Pending JP2025148430A (ja) | 2019-01-28 | 2025-07-09 | 多発性骨髄腫の処置方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11939390B2 (https=) |
| EP (2) | EP4588484A3 (https=) |
| JP (2) | JP7712206B2 (https=) |
| KR (1) | KR20210120048A (https=) |
| CN (2) | CN114026121A (https=) |
| AU (1) | AU2020215692A1 (https=) |
| BR (1) | BR112021014699A2 (https=) |
| CA (1) | CA3127928A1 (https=) |
| CO (1) | CO2021011034A2 (https=) |
| IL (2) | IL321343A (https=) |
| MA (1) | MA54860A (https=) |
| MX (1) | MX2021009079A (https=) |
| SG (1) | SG11202108029XA (https=) |
| TW (2) | TWI904081B (https=) |
| WO (1) | WO2020160020A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6279065B2 (ja) | 2013-03-13 | 2018-02-14 | サノフイ | 抗ｃｄ３８抗体およびカーフィルゾミブを含む組成物 |
| CN107135654B (zh) | 2014-09-12 | 2021-10-29 | 加利福尼亚大学董事会 | 巨胞饮人类抗cd46抗体和靶向癌症疗法 |
| US11939390B2 (en) | 2019-01-28 | 2024-03-26 | Sanofi-Aventis U.S. Llc | Methods of treating multiple myeloma |
| US20210171650A1 (en) * | 2019-05-14 | 2021-06-10 | Sanofi | Methods of administering anti-cd38 antibody |
| US11655302B2 (en) | 2019-06-10 | 2023-05-23 | Sanofi | Anti-CD38 antibodies and formulations |
| MX2022006882A (es) * | 2019-12-05 | 2022-11-08 | Sanofi Aventis Us Llc | Formulaciones de anticuerpos anti-cd38 para administracion subcutanea. |
| EP4192511A1 (en) * | 2020-08-07 | 2023-06-14 | Fortis Therapeutics, Inc. | Immunoconjugates targeting cd46 and methods of use thereof |
| IL302640A (en) * | 2020-11-03 | 2023-07-01 | Sanofi Aventis Us Llc | Use of isatuximab for the treatment of multiple myeloma |
| US20240058464A1 (en) * | 2021-01-07 | 2024-02-22 | Fortis Therapeutics, Inc. | Combination therapy with for46 for cancer |
| CN114219787B (zh) * | 2021-12-17 | 2024-08-06 | 三峡大学 | 一种初诊多发性骨髓瘤预后分期系统 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2567976B1 (en) * | 2005-03-23 | 2017-07-19 | Genmab A/S | Antibodies against CD38 for treatment of multiple myeloma |
| KR20130108481A (ko) | 2005-08-19 | 2013-10-02 | 아보트 러보러터리즈 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| NZ727295A (en) * | 2012-08-09 | 2018-06-29 | Celgene Corp | Treatment of immune-related and inflammatory diseases |
| US10617757B2 (en) * | 2014-08-08 | 2020-04-14 | The Regents Of The University Of California | Methods for treating multiple myeloma |
| PT3294769T (pt) * | 2015-05-13 | 2021-04-13 | Morphosys Ag | Tratamento para mieloma múltiplo (mm) |
| MX389805B (es) | 2015-05-20 | 2025-03-11 | Janssen Biotech Inc | Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras enfermedades malignas hematológicas positivas para cd38. |
| AU2016282674B2 (en) * | 2015-06-22 | 2022-01-13 | Janssen Biotech, Inc. | Combination therapies for heme malignancies with anti-CD38 antibodies and survivin inhibitors |
| GB201521217D0 (en) * | 2015-12-01 | 2016-01-13 | Oncopeptides Ab | Dosage regimens |
| KR20190091497A (ko) * | 2016-12-02 | 2019-08-06 | 루비우스 테라퓨틱스, 아이엔씨. | 고형 종양으로의 침투를 위한 세포 시스템과 관련된 조성물 및 방법 |
| WO2019012328A1 (en) * | 2017-07-09 | 2019-01-17 | Biosight Pharma | ANTICANCER POLY THERAPY |
| US11939390B2 (en) | 2019-01-28 | 2024-03-26 | Sanofi-Aventis U.S. Llc | Methods of treating multiple myeloma |
-
2020
- 2020-01-28 US US16/775,025 patent/US11939390B2/en active Active
- 2020-01-28 EP EP25172506.5A patent/EP4588484A3/en active Pending
- 2020-01-28 MA MA054860A patent/MA54860A/fr unknown
- 2020-01-28 BR BR112021014699A patent/BR112021014699A2/pt unknown
- 2020-01-28 CN CN202080024773.7A patent/CN114026121A/zh active Pending
- 2020-01-28 CN CN202510783436.0A patent/CN120754030A/zh active Pending
- 2020-01-28 MX MX2021009079A patent/MX2021009079A/es unknown
- 2020-01-28 WO PCT/US2020/015455 patent/WO2020160020A1/en not_active Ceased
- 2020-01-28 AU AU2020215692A patent/AU2020215692A1/en active Pending
- 2020-01-28 IL IL321343A patent/IL321343A/en unknown
- 2020-01-28 KR KR1020217027098A patent/KR20210120048A/ko active Pending
- 2020-01-28 CA CA3127928A patent/CA3127928A1/en active Pending
- 2020-01-28 EP EP20706606.9A patent/EP3917961A1/en active Pending
- 2020-01-28 JP JP2021543372A patent/JP7712206B2/ja active Active
- 2020-01-28 IL IL285110A patent/IL285110B2/en unknown
- 2020-01-28 SG SG11202108029XA patent/SG11202108029XA/en unknown
- 2020-01-30 TW TW109102902A patent/TWI904081B/zh active
- 2020-01-30 TW TW114114347A patent/TW202535952A/zh unknown
-
2021
- 2021-08-23 CO CONC2021/0011034A patent/CO2021011034A2/es unknown
-
2024
- 2024-02-16 US US18/443,878 patent/US20240190984A1/en active Pending
-
2025
- 2025-07-09 JP JP2025115594A patent/JP2025148430A/ja active Pending